A detailed history of State Of Alaska, Department Of Revenue transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, State Of Alaska, Department Of Revenue holds 47,975 shares of VRTX stock, worth $22.5 Million. This represents 0.24% of its overall portfolio holdings.

Number of Shares
47,975
Previous 50,345 4.71%
Holding current value
$22.5 Million
Previous $23.6 Million 5.45%
% of portfolio
0.24%
Previous 0.26%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 24, 2024

SELL
$460.0 - $505.78 $1.09 Million - $1.2 Million
-2,370 Reduced 4.71%
47,975 $22.3 Million
Q2 2024

Aug 05, 2024

BUY
$392.81 - $485.53 $133,555 - $165,080
340 Added 0.68%
50,345 $23.6 Million
Q1 2024

Apr 19, 2024

SELL
$407.69 - $446.08 $1.18 Million - $1.29 Million
-2,890 Reduced 5.46%
50,005 $20.9 Million
Q4 2023

Jan 19, 2024

SELL
$343.0 - $410.68 $171,500 - $205,340
-500 Reduced 0.94%
52,895 $21.5 Million
Q3 2023

Oct 16, 2023

SELL
$338.18 - $362.46 $424,415 - $454,887
-1,255 Reduced 2.3%
53,395 $18.6 Million
Q2 2023

Jul 24, 2023

SELL
$314.42 - $351.91 $2.72 Million - $3.05 Million
-8,664 Reduced 13.68%
54,650 $19.2 Million
Q1 2023

Apr 17, 2023

BUY
$283.23 - $323.1 $1,132 - $1,292
4 Added 0.01%
63,314 $19.9 Million
Q4 2022

Jan 11, 2023

BUY
$285.76 - $321.48 $1.98 Million - $2.23 Million
6,940 Added 12.31%
63,310 $18.3 Million
Q3 2022

Oct 20, 2022

BUY
$273.83 - $305.53 $437,580 - $488,236
1,598 Added 2.92%
56,370 $16.3 Million
Q2 2022

Jul 08, 2022

BUY
$234.96 - $292.55 $4.45 Million - $5.55 Million
18,957 Added 52.93%
54,772 $15.4 Million
Q1 2022

Apr 14, 2022

SELL
$221.42 - $260.97 $218,098 - $257,055
-985 Reduced 2.68%
35,815 $9.35 Million
Q4 2021

Jan 12, 2022

SELL
$177.01 - $223.45 $537,225 - $678,170
-3,035 Reduced 7.62%
36,800 $8.08 Million
Q3 2021

Oct 07, 2021

SELL
$181.39 - $202.99 $818,613 - $916,093
-4,513 Reduced 10.18%
39,835 $7.23 Million
Q2 2021

Jul 12, 2021

BUY
$187.49 - $221.1 $678,526 - $800,160
3,619 Added 8.89%
44,348 $8.94 Million
Q1 2021

Apr 09, 2021

SELL
$207.02 - $241.31 $375,120 - $437,253
-1,812 Reduced 4.26%
40,729 $8.75 Million
Q4 2020

Jan 08, 2021

SELL
$207.01 - $276.09 $505,518 - $674,211
-2,442 Reduced 5.43%
42,541 $10.1 Million
Q3 2020

Oct 05, 2020

SELL
$255.65 - $303.1 $2.78 Million - $3.3 Million
-10,876 Reduced 19.47%
44,983 $12.2 Million
Q2 2020

Jul 06, 2020

BUY
$225.48 - $295.8 $2.48 Million - $3.26 Million
11,015 Added 24.56%
55,859 $16.2 Million
Q1 2020

Apr 06, 2020

BUY
$199.77 - $247.81 $175,597 - $217,824
879 Added 2.0%
44,844 $10.7 Million
Q4 2019

Jan 07, 2020

SELL
$166.71 - $223.91 $576,816 - $774,728
-3,460 Reduced 7.3%
43,965 $9.63 Million
Q3 2019

Oct 02, 2019

BUY
$166.23 - $187.09 $1.15 Million - $1.29 Million
6,890 Added 17.0%
47,425 $8.03 Million
Q2 2019

Jul 23, 2019

BUY
$164.61 - $190.37 $25,185 - $29,126
153 Added 0.38%
40,535 $7.43 Million
Q1 2019

Apr 09, 2019

SELL
$163.73 - $194.7 $103,149 - $122,661
-630 Reduced 1.54%
40,382 $7.43 Million
Q4 2018

Jan 10, 2019

BUY
$151.91 - $192.21 $9,722 - $12,301
64 Added 0.16%
41,012 $6.8 Million
Q3 2018

Oct 09, 2018

SELL
$167.73 - $192.74 $13,753 - $15,804
-82 Reduced 0.2%
40,948 $7.89 Million
Q2 2018

Jul 10, 2018

BUY
$145.72 - $169.96 $827,981 - $965,712
5,682 Added 16.07%
41,030 $6.97 Million
Q1 2018

Apr 19, 2018

BUY
$151.6 - $177.13 $647,332 - $756,345
4,270 Added 13.74%
35,348 $5.76 Million
Q4 2017

Jan 19, 2018

BUY
$137.28 - $155.55 $3.43 Million - $3.89 Million
25,008 Added 411.99%
31,078 $4.66 Million
Q3 2017

Oct 16, 2017

BUY
$148.13 - $162.24 $899,149 - $984,796
6,070
6,070 $922,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $120B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track State Of Alaska, Department Of Revenue Portfolio

Follow State Of Alaska, Department Of Revenue and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of State Of Alaska, Department Of Revenue, based on Form 13F filings with the SEC.

News

Stay updated on State Of Alaska, Department Of Revenue with notifications on news.